Noninvasive assessment of characteristics of novel anti-HER2

Changes in ERa expression in response to HER2-directed therapy in the

Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)

Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer

Cancers, Free Full-Text

Novel Aptamers Selected on Living Cells for Specific Recognition of Triple-Negative Breast Cancer - ScienceDirect

Noninvasive assessment of characteristics of novel anti-HER2 antibodies by molecular imaging in a human gastric cancer xenograft-bearing mouse model

Binding assay of the purified anti-HER2 scFv expressed from BL21 (DE3)

IJMS, Free Full-Text

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The

Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer

Cancers, Free Full-Text

HER2 targeted noninvasive immunosensor based on pencil graphite electrode for detection of breast cancer - ScienceDirect

Schematic diagram of the pET-22 expressing anti-HER2 scFv. The